本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2023-056 （一）会议召开情况 江苏森萱医药股份有限公司 第三届监事会第二十次会议决议公告 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事封乃军因出差以通讯方式参与表决 监事秦建因出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2023 年第三季度报告>的议案》 1.议案内容： 具 体 内 容 详 见 公 司 于 同 日 在 北 京 证 券 交 易 所 信 息 披 露 平 台 （http://www.bse.cn）披露的《2023 年第三季度报告》（公告编号： 2023-054） 1.会议召开时间：2023 年 10 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2023 年 10 月 13 日以书面、邮件方式发出 5.会议主持人：秦建 6.召开情况合 ...

Financial Performance - Operating revenue for the first nine months of 2023 was CNY 445,083,009.80, down 10.74% year-on-year[12] - Net profit attributable to shareholders for the first nine months of 2023 was CNY 103,319,227.37, a decline of 24.79% compared to the same period last year[12] - Basic earnings per share for the first nine months of 2023 decreased to CNY 0.2420, down 24.80% from CNY 0.3218 in the previous year[12] - Cash flow from operating activities for the first nine months of 2023 was CNY 110,327,988.09, a decrease of 23.17% year-on-year[12] - Total revenue for the period was 397,744,647.74, a slight decrease from 402,109,622.46 in the previous year[19] - Operating costs were 213,371,632.21, compared to 216,799,651.23 in the previous year, reflecting a decrease in expenses[19] - The net cash flow from investment activities decreased by 276.53% to -49,980,528.60, primarily due to reduced inflows from bank financial products[14] - The company reported a significant increase in trading financial assets, rising to CNY 116,274,068.49 from CNY 74,622,835.62, marking a growth of approximately 55.8%[74] - The company reported a financial income of CNY 10,785,997.77 for the first nine months of 2023, an increase from CNY 8,799,936.17 in 2022[83] Assets and Liabilities - Total assets as of September 30, 2023, amounted to CNY 1,288,585,209.69, a decrease of 0.35% compared to the end of 2022[12] - The company's asset-liability ratio (consolidated) improved to 8.51% from 10.55% at the end of 2022[12] - Accounts receivable increased by 250.43%, reaching CNY 8,178,331.61, primarily due to increased business settled by bills[13] - Contract liabilities decreased by 42.57% to CNY 5,786,142.19, attributed to a reduction in advance payments from customers[13] - Total liabilities as of September 30, 2023, were CNY 5,002,073.82, a decrease from CNY 6,019,985.13 at the end of 2022[80] - Shareholders' equity as of September 30, 2023, was CNY 755,035,010.05, down from CNY 830,324,306.90 at the end of 2022[80] Cash Flow - Cash and cash equivalents at the end of the period were 335,034,617.05, down from 339,223,548.70 in the previous year[19] - Cash received from investment activities decreased by 69.42% to 74,000,000.00, mainly due to fewer matured financial products being recovered[14] - The cash inflow from operating activities for the first nine months of 2023 is CNY 409,289,943.64, a decrease from CNY 433,190,969.91 in 2022, representing a decline of about 5.5%[89] - The net cash flow from operating activities decreased to ¥110,327,988.09 from ¥143,601,097.86, representing a decline of approximately 23%[91] - Cash inflow from investment activities totaled ¥76,265,336.98, down from ¥245,991,831.87, indicating a decrease of about 69%[91] Shareholder Information - Total outstanding shares at the end of the period were 426,918,340, with 99.9561% being freely tradable shares[21] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 308,724,340 shares, representing 72.3146% of total shares[23] - The total number of common shareholders is 11,086[21] - The company has no litigation or arbitration matters during the reporting period[27] - There were no significant changes in the shareholding structure during the reporting period[23] Commitments and Governance - The company commits to stabilizing its stock price for three years after the public offering, initiating measures if the stock price falls below the audited net asset value per share[35] - The company has ongoing commitments related to avoiding competition and regulating related transactions, which are currently being fulfilled[32] - The controlling shareholder has made commitments to not interfere with the company's management or harm its interests[44] - The company will ensure that the remuneration system for directors is linked to the execution of compensation measures[45] - The company will provide supplementary or alternative commitments to protect the interests of shareholders and investors in case of unforeseen circumstances[63] Profit Distribution Policy - A profit distribution policy has been developed to enhance transparency and ensure stable returns for investors, with a focus on continuous and stable profit distribution[47] - The company plans to distribute profits primarily in cash, with a preference for cash dividends over stock dividends[49] - The company commits to a cash dividend distribution at least once per fiscal year, barring negative earnings or other special circumstances[49] - The company plans to distribute cash dividends of no less than 10% of the distributable profits achieved in the current year when conditions for cash dividends are met[51] - In the past three consecutive fiscal years, the cumulative cash dividends distributed by the company must not be less than 30% of the average annual distributable profits for those three years[51]

江苏森萱医药股份有限公司 证券代码:830946 证券简称:森萱医药 公告编号:2023-053 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏森萱医药股份有限公司(以下简称"公司")于 2023 年 9 月 13 日接待 了 16 家机构的调研,现将主要情况公告如下: 一、 调研情况 调研时间:2023 年 9 月 13 日 调研形式:电话调研 调研机构:开源证券、谈水泉(北京)投资管理有限公司、聚鸣投资、嘉实 基金、上海勤辰私募基金管理合作企业(有限合伙)、进门财经、深圳市尚诚资 产管理有限责任公司、泰康资产管理有限公司、深圳市坤厚私募证券投资基金管 理有限公司、鸿运私募基金管理(海南)有限公司、宁波东玛私募基金管理有限 公司、杭州萧山泽泉投资管理有限公司、国泰基金、工银国际控股有限公司、深 圳中天汇富基金管理有限公司、华夏财富 上市公司接待人员:董事长吴玉祥,董事会秘书、财务负责人朱狮章 二、 调研的主要问题及公司回复概要 问题一: ...

江苏森萱医药股份有限公司 证券代码:830946 证券简称:森萱医药 公告编号:2023-052 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假 记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 江苏森萱医药股份有限公司(以下简称"公司")于 2023 年 9 月 12 日接 待了 2 家机构的调研,现将主要情况公告如下: 一、 调研情况 调研时间:2023 年 9 月 12 日 调研形式:网络调研 调研机构:天弘基金、开源证券 上市公司接待人员:董事长吴玉祥,董事会秘书、财务负责人朱狮章 二、 调研的主要问题及公司回复概要 问题一:请简单介绍一下公司上半年的经营情况 回复:公司在 8 月底公布了半年报,上半年度公司实现营业收入 3.18 亿, 同比下降 9.61%;实现归属于上市公司的净利润 7,663.22 万元,同比下降 19.82%;实现经营活动产生的现金流量净额 5,799.93 万元,同比下降 27.30%。 从主要经济指标看,公司上半年的经营业绩出现了一定程度的下滑,但总体平 稳 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2023-049 江苏森萱医药股份有限公司 第三届董事会第二十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2.会议召开地点：公司会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2023 年 8 月 11 日以书面、邮件等方 式发出 5.会议主持人：吴玉祥 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 24 日 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事袁拥军因出差以通讯方式参与表决。 董事姜春娟因出差以通讯方式参与表决。 董事任勇因出差以通讯方式参与表决。 二、议案审议情况 江苏森萱医药股份有限公司 （一）审议通过《关于审议<2023 年半年度报告>及<2023 ...

证券代码：830946 证券简称：森萱医药 公告编号：2023-050 江苏森萱医药股份有限公司 江苏森萱医药股份有限公司 （一）会议召开情况 1.会议召开时间：2023 年 8 月 24 日 2.会议召开地点：公司会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2023 年 8 月 11 日 以书面、邮件方式发 出 5.会议主持人：秦建 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 （一）审议通过《关于审议<2023 年半年度报告>及<2023 年半年度报告摘要>的 议案 》 1.议案内容： 具体内容详见公司于同日在北京证券交易所信息披露平台 江苏森萱医药股份有限公司 三、备查文件目录 经与会监事确认签字并加盖监事会印章的《江苏森萱医药股份有限公司第三 届监事会第十九次会议决议》 江苏森萱医药股份有限公司 第三届监事会第十九次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 江苏森萱医药股份有限公司2023年8月24日召开第三届董事会第二十一次会议。 我们作为公司独立董事，根据《中华人民共和国公司法》(以下简称"《公司法》") 《中华人民共和国证券法》《北京证券交易所股票上市规则(试行)》《北京证 江苏森萱医药股份有限公司 证券代码： 830946 证券简称：森萱医药 公告编号：2022-051 《公司章程》及公司《独立董事工作细则》等有关规定，本着审慎、负责任的态度， 基于独立判断，对公司第三届董事会第二十一次会议审议的相关事项发表独立意见 如下： 经审阅《关于审议<关于2023年1-6月募集资金存放与使用情况的专项报告> 的议案》，我们认为：公司2023年1-6月份对募集资金存放与使用，符合中国证 监会《上市公司监管指引第2号—上市公司募集资金管理和使用的监管要求》 (2022 年修订) 和《北京证券交易所股票上市规则(试行)》相关要求，决策程序 合法合规，不存在损害中小股东利益的情形。董事会审议该议案时，审议和表决 程序 ...

江苏森萱医药股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2023-048 一、募集资金基本情况 （一）2020 年公开发行募集资金基本情况 经中国证券监督管理委员会《关于核准江苏森萱医药股份有限公司向不特定 合格投资者公开发行股票的批复》（证监许可[2020]1302 号），核准公司向不特 定合格投资者公开发行不超过 9,000 万股新股，公司第三届董事会第二次会议在 股东大会的授权范围内确定最终发行股份为 6,000 万股，经询价后和主办券商开 源证券股份有限公司确定本次发行价格人民币 5.40 元/股，募集资金总额人民币 32,400.00 万元，公司募集资金扣除需支付的承销、保荐费用 2,106.00 万元后 的 30,294.00 万元已于 2020 年 7 月 16 日全部存入公司开立的江苏张家港农村商 业银行股份有限公司南通分行的 8020188800660 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 317,588,772.54, a decrease of 9.61% compared to CNY 351,367,667.65 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was CNY 76,632,214.85, down 19.82% from CNY 95,570,133.06 year-on-year[26]. - The gross profit margin decreased to 42.98% from 47.02% in the previous year[26]. - The net profit for the period was ¥80.52 million, down 20.91% from ¥101.80 million in the previous year[48]. - The company reported a total revenue of CNY 262,682,698.06 from sales of goods and services in the first half of 2023, down from CNY 273,094,837.08 in the same period of 2022[179]. - The company reported a significant increase in trading financial assets, rising to CNY 141,152,369.86 from CNY 74,622,835.62, an increase of about 88.9%[164]. - The company reported a comprehensive income of $80,516,417.50 for the current period, compared to a lower figure in the previous period[187]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,250,208,414.31, a decline of 3.32% from CNY 1,293,147,896.31 at the end of the previous year[27]. - Total liabilities decreased by 26.46% to CNY 100,302,125.15 from CNY 136,386,510.76 year-on-year[27]. - Cash and cash equivalents decreased by 22.30% to ¥375.33 million, accounting for 30.02% of total assets[43]. - Accounts receivable increased by 23.06% to ¥58.78 million, representing 4.70% of total assets[43]. - The total number of shares at the end of the period is 426,918,340, with 99.9561% being unrestricted shares[146]. Research and Development - R&D expenses decreased by 21.10% to ¥14.02 million, representing 4.41% of revenue[47]. - The company has 12 types of raw material drug technologies that are currently under evaluation for mass production, with the evaluation timeline being uncertain[93]. - The company plans to continue expanding its market presence and developing new products, as evidenced by the successful trial production of the formaldehyde slice project[7]. Environmental Compliance - The company adheres to environmental protection standards and regulations in its operations[64]. - The company has implemented various environmental protection standards including GB31571-2015 and GB37823-2019 for air and wastewater emissions[69]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[88]. - The company has established a self-built sewage station for the treatment of combined industrial and domestic wastewater[76]. Shareholder Commitments - The company is currently fulfilling commitments related to stabilizing stock prices since May 19, 2020[105]. - The company has committed to a stable and continuous profit distribution policy, prioritizing cash dividends to enhance transparency and shareholder returns[124]. - The controlling shareholder has committed to not interfere with the company's management or misappropriate its interests[120]. - The company will ensure that any adjustments to the profit distribution policy are thoroughly justified and approved by the shareholders[124]. Risks and Challenges - The company faces tax policy risks due to potential loss of high-tech enterprise tax benefits, which could impact operations[91]. - Currency exchange rate fluctuations pose risks to the company’s export pricing and competitiveness, with measures in place to mitigate these risks[92]. - The company is increasing R&D investments to address market competition risks from both domestic and international players[92]. Operational Efficiency - The company has committed to enhancing management efficiency and controlling expenses to improve operational performance and profitability[118]. - The company plans to propose profit distribution or capital reserve conversion to stabilize stock prices if necessary[113]. - The company will establish a special account for the management of raised funds to ensure their proper and efficient use[119].